C12Y 301/06012
N-acetylgalactosamine-4-sulfatase
Official title: N-Acetylgalactosamine-4-sulfatase (3.1.6.12)
C12Y301/06012 (N-acetylgalactosamine-4-sulfatase) appears on 3 US grants and 15 published applications in this corpus.
Search patents in C12Y- Granted patents
- 3
- Published applications
- 15
- Assignees
- 12
- Inventors
- 36
- Latest grant
- 15 Jun 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 2 |
| 2005 | 2 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 2 |
| 2020 | 0 | 1 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 2 |
| 2025 | 0 | 3 |
By publication year.
Recent patents
- Delivering enzyme using an injectable hydrogel depot15 Jun 2021US 11,034,950 B2Saint Louis University
- Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme6 Dec 2005US 6,972,124 B2BioMarin Pharmaceuticals
- Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme15 Mar 2005US 6,866,844 B2Biomarin Pharmaceutical Inc.
- Homology independent targeted integration for gene editing18 Sep 2025US 2025/0288694 A1Fondazione Telethon Ets
- Compositions and methods for defining optimal treatment timeframes in lysosomal disease19 Jun 2025US 2025/0194571 A1Regeneron Pharmaceuticals, Inc.
- Therapies for mucopolysaccharidosis type 61 May 2025US 2025/0136671 A1National Research Council of Canada
- Arsb vectors for treatment of mps vi-associated blindness and other ocular manifestations30 May 2024US 2024/0173386 A1North Carolina State University
- Compositions, devices and methods for treating mps vi disease18 Apr 2024US 2024/0123040 A1Sigilon Therapeutics, Inc.
Most cited
By later US patents